You are here
Clinical Trials: Eye Disease
Discuss
Each Clinical Trial will open in a new browser window or tab.
Condition: Macular Holes
Intervention: Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)
Sponsor: Tianjin Medical University
Recruiting
Intervention: Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)
Sponsor: Tianjin Medical University
Recruiting
Conditions: Ocular Discomfort; Ocular Inflammation; Dry Eye; Contact Lens Complication; Keratoconjunctivitis Sicca
Intervention: Drug: Lifitegrast
Sponsors: University of Alabama at Birmingham; Shire
Not yet recruiting
Intervention: Drug: Lifitegrast
Sponsors: University of Alabama at Birmingham; Shire
Not yet recruiting
Conditions: Dry Eye Syndromes; Dry Eye; Ocular Inflammation; Ocular Surface Disease; Ocular Discomfort; Blepharitis
Intervention: Other: Corneal Epithelial Stem Cell Transplant
Sponsor: Sloan W. Rush, MD
Recruiting
Intervention: Other: Corneal Epithelial Stem Cell Transplant
Sponsor: Sloan W. Rush, MD
Recruiting
Conditions: Corneal Haze After Photo Therapeutic/Refractive Keratectomy; Corneal Haze After Collagen Cross Linking
Interventions: Biological: stem cells after standard surgical therapy; Other: Vehicle
Sponsor: L.V. Prasad Eye Institute
Recruiting
Interventions: Biological: stem cells after standard surgical therapy; Other: Vehicle
Sponsor: L.V. Prasad Eye Institute
Recruiting
Condition: Non Arteritic Ischemic Optic Neuropathy
Intervention: Procedure: intravitreal injection of MSV
Sponsors: Instituto Universitario de Oftalmobiología Aplicada; University of Valladolid
Not yet recruiting - verified June 2017
Intervention: Procedure: intravitreal injection of MSV
Sponsors: Instituto Universitario de Oftalmobiología Aplicada; University of Valladolid
Not yet recruiting - verified June 2017
Condition: Age-Related Macular Degeneration
Interventions: Drug: ASP7317; Other: Placebo; Drug: Prograf®; Drug: mycophenolate mofetil (MMF)
Sponsor: Astellas Institute for Regenerative Medicine
Not yet recruiting - verified June 2017
Interventions: Drug: ASP7317; Other: Placebo; Drug: Prograf®; Drug: mycophenolate mofetil (MMF)
Sponsor: Astellas Institute for Regenerative Medicine
Not yet recruiting - verified June 2017
Condition: Retinitis Pigmentosa
Intervention: Biological: human retinal progenitor cells
Sponsor: jCyte, Inc
Recruiting - verified March 2017
Intervention: Biological: human retinal progenitor cells
Sponsor: jCyte, Inc
Recruiting - verified March 2017
Condition: Dry Age-related Macular Degeneration
Intervention: Biological: retinal pigment epithelium transplantation
Sponsors: Chinese Academy of Sciences; The First Affiliated Hospital of Zhengzhou University
Recruiting - verified December 2016
Intervention: Biological: retinal pigment epithelium transplantation
Sponsors: Chinese Academy of Sciences; The First Affiliated Hospital of Zhengzhou University
Recruiting - verified December 2016
Conditions: Retinal Disease; Age-Related Macular Degeneration; Retinitis Pigmentosa; Stargardt Disease; Optic Neuropathy; Nonarteritic Ischemic Optic Neuropathy; Optic Atrophy; Optic Nerve Disease; Glaucoma; Leber Hereditary Optic Neuropathy
Interventions: Procedure: Arm 1; Procedure: Arm 2; Procedure: Arm 3
Sponsor: MD Stem Cells
Recruiting - verified January 2017
Interventions: Procedure: Arm 1; Procedure: Arm 2; Procedure: Arm 3
Sponsor: MD Stem Cells
Recruiting - verified January 2017
Conditions: Corneal Injuries; Corneal Burns; Corneal Scars and Opacities
Intervention: Biological: Ex-vivo cultivated limbal stem cell pool
Sponsor: L.V. Prasad Eye Institute
Recruiting - verified October 2016
Intervention: Biological: Ex-vivo cultivated limbal stem cell pool
Sponsor: L.V. Prasad Eye Institute
Recruiting - verified October 2016
